ViroMed Receives Approval for Diabetic Neuropathy Phase I/II Trial

ViroMed has received approval from the US Food and Drug Administration (FDA) to start clinical trials for diabetic neuropathy, a major complication of diabetes mellitus.

The Phase I/II clinical trial will take place at various medical centers, including Northwestern Memorial Hospital, under the guidance of Dr Douglas Losordo, Director, Feinberg Cardiovascular Research Institute.

“The clinical trial approval of VM202-DPN allows us not only to anticipate the globalization of Korean technology and the possibility of a new worldwide drug,” says Dr Kim, “but also to look forward to an improvement in the quality of life for patients with diabetes who have no other alternatives.”